12 month evolution of biochemical and virological parameters according to treatment groups
 |
| |||
12 month evolution of biochemical and virological parameters according to treatment groups
| ADV group (n = 29) | p | TDF group (N = 56) | p | |||
|---|---|---|---|---|---|---|
| baseline | 12 months | baseline | 12 months | |||
| HBV-DNA log10 copies/mL, median (Q1 – Q3)1 | 8.30 (6.56 – 9.10) | 3.87 (2.95 – 5.60) | <0.0001 | 7.30 (6.00 – 8.30) | 2.47 (2.30 – 3.52) | <0.0001 |
| Presence of HBe Antigen (n, %)2 | 21 (87.5) | 17 (70.8) | 0.02 | 47 (88.7) | 40 (75.5) | 0.002 |
| Presence of antiHBe Antibody (n, %)2 | 4 (20.0) | 5 (25.0) | 0.001 | 6 (11.5) | 8 (15.4) | <0.001 |
| ALT IU/L, mean (SD)1 | 134 (150) | 83 (79) | ns | 90 (93) | 46 (29) | 0.001 |
| AST IU/L, mean (SD)1 | 112 (102) | 72 (80) | ns | 66 (74) | 33 (11) | 0.001 |
| g-Glutamyl Transferase IU/L, mean (SD)3 | 136 (223) | 74 (75) | ns | 81 (95) | 60 (67) | ns |
| ALP IU/L, mean (SD)3 | 104 (63) | 101 (57) | ns | 85 (33) | 79 (24) | ns |
| Creatinine Clearance ml/min, mean (SD)3 | 103.8 (17.8) | 94.2 (19.5) | 0.02 | 95.3 (32.5) | 100.0 (23.2) | ns |
| CD4+ cell count/mm3, mean (SD)3 | 482 (298) | 488 (402) | ns | 457 (250) | 501 (238) | 0.01 |
| HIV-RNA log10 copies/mL, median (IQR)1 | 1.88 (1.70–5.20) | 1.70 (1.70–5.67) | ns | 1.85 (1.70–6.19) | 1.70 (1.70–3.84) | <0.0001 |